Search

The sensitive and specific detection of peptides at low levels in biofluids is critical to increase the lab-to-human translation of peptidomic research. An interesting group of peptides with increasing evidence for involvement in human diseases are quorum sensing peptides. To obtain more reliable conclusions on peptide measurands in biofluids, a selection of often neglected parts of the analytical process using LC-MS were investigated, with novel approaches recommended for each part. Quorum sensing peptides were used as the main model-peptides. The peptidomic parts investigated and discussed here are: Our work addresses aQbD-approached solutions to these challenges, encompassing sample stabilization measures, a suitable peptide anti-adsorption tool, judicious choice of injection solvent versus gradient system and optimal duty cycle parameters. Our recommendations will improve the peptidomics bio-analytics of not only quorum sensing peptides, but can also be of value for other measurands at low concentrations., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Quorum-sensing peptides (QSPs) are bacterial peptides traditionally considered only as inter-bacterial communication molecules. Recently, their involvement in microbiome-host interactions influencing host diseases such as cancer and sarcopenia were explored. However, it is still unknown to what extent these peptides have the potential to modulate the immune system. In this proof-of-concept study, we screened 89 QSPs for their potential to induce IL-6 and TNFα in murine splenocytes and J774 macrophages. Confirmatory experiments on the positive screening-hits were conducted using murine splenocytes and human PBMCs of different ages. Finally, to investigate the biological relevance of immunomodulatory QSPs, we analysed plasma in a human cohort for the presence of the immunomodulatory QSP Q010. To do this, we used a newly developed UHPLC-MS/MS method. Our findings indicated that specific QSPs activate immune cells in vitro, with Q007, Q010, Q017 and Q212 being the top four screening hits. Q007 and Q010 were affirmed in subsequent confirmatory experiments using murine splenocytes and human PBMCs. Finally, Q010 was detected in human plasma, demonstrating for the first time the presence of an immunomodulatory QSP in human circulation. In conclusion, our data are the first evidence indicating the potential of biologically relevant quorum-sensing peptides to modulate the immune system.

Quorum sensing peptides (QSPs) are bacterial peptides produced by Gram-positive bacteria to communicate with their peers in a cell-density dependent manner. These peptides do not only act as interbacterial communication signals, but can also have effects on the host. Compelling evidence demonstrates the presence of a gut-brain axis and more specifically, the role of the gut microbiota in microglial functioning. The aim of this study is to investigate microglial activating properties of a selected QSP (PapRIV) which is produced by Bacillus cereus species. PapRIV showed in vitro activating properties of BV-2 microglia cells and was able to cross the in vitro Caco-2 cell model and reach the brain. In vivo peptide presence was also demonstrated in mouse plasma. The peptide caused induction of IL-6, TNFα and ROS expression and increased the fraction of ameboid BV-2 microglia cells in an NF-κB dependent manner. Different metabolites were identified in serum, of which the main metabolite still remained active. PapRIV is thus able to cross the gastro-intestinal tract and the blood-brain barrier and shows in vitro activating properties in BV-2 microglia cells, hereby indicating a potential role of this quorum sensing peptide in gut-brain interaction.

(C) iAM373 concentrations in faeces and plasma of germ-free mice untreated (untreated), gavaged with wild-type E. coli (placebo) or gavaged with E. coli expressing iAM373 (iAM373). Dear Editor, Sarcopenia - the accelerated loss of muscle mass, strength and function with ageing - represents an important health challenge with reduced quality of life and increased mortality.1 Gut microbiota has been suggested to contribute to this age-associated muscle wasting but the underlying mechanisms are still unclear.2 Here, we uncover the quorum sensing peptide iAM373 as a hitherto unknown contributor to sarcopenia. [Extracted from the article]

Muscle wasting diseases, such as cancer cachexia and age-associated sarcopenia, have a profound and detrimental impact on functional independence, quality of life, and survival. Our understanding of the underlying mechanisms is currently limited, which has significantly hindered the development of targeted therapies. In this study, we explored the possibility that the streptococcal quorum sensing peptide Competence Stimulating Peptide 7 (CSP-7) might be a previously unidentified contributor to clinical muscle wasting. We found that CSP-7 selectively triggers muscle cell inflammation in vitro , specifically the release of IL-6. Furthermore, we demonstrated that CSP-7 can traverse the gastrointestinal barrier in vitro and is present in the systemic circulation in humans in vivo. Importantly, CSP-7 was associated with a muscle wasting phenotype in mice in vivo. Overall, our findings provide new mechanistic insights into the pathophysiology of muscle inflammation and wasting. • Streptococcal quorum sensing peptide CSP-7 emerges as a previously unrecognized factor in skeletal muscle homeostasis. • CSP-7 triggers the production of IL-6 in muscle cells in vitro. • CSP-7 induces muscle wasting in mice in vivo. • CSP-7 is present in human systemic circulation. [ABSTRACT FROM AUTHOR]

• Selected Streptococcal Competence Stimulating peptides were detected in saliva by UHPLC-MS/MS. • A fit-for-purpose UHPLC-MS/MS method wasdeveloped and verified for the analysis of selected Streptococcal CompetenceStimulating peptides in human saliva. • The sample preparation incorporates ananti-adsorption diluent to prevent loss due to adsorption of the quorum sensingpeptides. • Presence of Streptococcal Competence StimulatingPeptides in saliva was demonstrated by UHPLC-MS/MS. [Display omitted] The development of analytical methods for the detection of peptides at the nanomolar level can be challenging. Peptides can suffer from adsorption, rendering the detection of peptides at these low levels difficult. A subset of peptides are the quorum sensing peptides, which are bacterial communication molecules demonstrating possible host effects as well. However, their direct presence in human biofluids has only rarely been reported. Therefore, a UHPLC-MS/MS method capable of detecting 15 selected Streptococcal competence stimulating quorum sensing peptides at the nanomolar level in human saliva was developed. This method, using an anti-adsorption diluent, was applied on saliva samples obtained from 38 healthy donors. Six donors did have a positive hit for at least one of three competence stimulating quorum sensing peptides using a triple quadrupole assay. These observations indicate that Streptococcus species produce quorum sensing peptides in the human oral cavity. [ABSTRACT FROM AUTHOR]